Seed Round

Isomorphic Labs is a London-based company that leverages artificial intelligence for computational drug design, aiming to transform the drug discovery process and accelerate the development of life-changing medicines. Founded in 2021 by AI pioneer Demis Hassabis, the company has quickly gained attention for its innovative approach to drug design. The recent funding will be utilized to enhance their AI-driven drug discovery platform and expedite the development of new therapeutics. This funding round is notable as it marks the company's first external investment, significantly boosting its capabilities in the biotech sector. The funding was led by prominent investors including Dragonfly Capital and Pantera Capital, with additional backing from Alphabet, the parent company of Google, which has a vested interest in AI and biotech innovations. This significant investment of $600 million will enable Isomorphic Labs to further develop its cutting-edge technology and expand its research initiatives. The company was spun out of Google DeepMind and is positioned to be a leader in the intersection of AI and drug discovery.